Harbour BioMed acquired global rights (ex-China) to a PD-L1 candidate from Sichuan Kelun-Biotech in a deal worth up to $350 million. Kelun-Biotech is currently testing A167 (KL-A167) in several China Phase I and II trials among patients with lymphoma ...


ChinaBio® Weekly Update

Contents


Harbour BioMed in $350 Million Deal for Sichuan Kelun PD-L1 Candidate

Written by Richard Daverman, PhD, Executive Editor, Greg B. Scott.

Harbour BioMed acquired global rights (ex-China) to a PD-L1 candidate from Sichuan Kelun-Biotech in a deal worth up to $350 million. Kelun-Biotech is currently testing A167 (KL-A167) in several China Phase I and II trials among patients with lymphoma and solid tumors. Harbour plans to conduct A167 trials in combination with its own innovative compounds and in collaborations with partners' drugs. Harbour has an R&D site in Shanghai, headquarters in Boston and an antibody discovery operations in Holland. More details....

Share this with colleagues:

     
 

Harbin Gloria Partners Four of its Drug Candidates in $53 Million Agreement

Written by Richard Daverman, PhD, Executive Editor, Greg B. Scott.

Harbin Gloria Pharma restructured its development program by forming a $53 million consortium with four investors. The consortium will have rights to four Gloria development-stage assets. 6 Dimensions, Boyu Capital and two other investors will acquire a 51% stake in Guangzhou Gloria Biotech for $27 million. Gloria will invest $26 million for the remaining 49%. The new subsidiary will be in charge of development of the four assets, including a PD-1 clinical stage candidate. More details....

Stock Symbol: (SZE: 002437)

Share this with colleagues:

     
 

Week in Review: Shanghai ChemPartner, a China CRO/CMO, Completes Reverse Merger

Written by Richard Daverman, PhD, Executive Editor, Greg B. Scott.

Deals and Financings 

  • Shanghai ChemPartner, a CRO/CMO, closed its reverse merger with Quantum Hi-Tech China Biological at an undisclosed valuation; 
  • YiChang HEC ChangJiang Pharm raised $400 million from Blackstone Group via a convertible bond offering representing a 15% share in HEC;
  • The Buck Institute for Research on Aging, Insilico and Juvenescence joined together to form Napa Therapeutics, a company using AI to develop an anti-aging drug;
  • Haisco Pharma invested $10 million in Pneuma Respiratory in return for China rights to Pneumahaler™, a novel asthma/COPD inhaler;
  • Crown Biosciences, a global CRO, in-licensed rights to translational mouse platforms developed by Shanghai Model Organisms Center;

Company News

  • Adlai Nortye, a Hangzhou biopharma, opened a Boston site that will be the company's target validation and translational medicine center;

Trials and Approvals

  • Sirnaomics of Maryland was approved to start US trials of its anti-cancer/anti-fibrosis siRNA therapeutic in patients with advanced cholangiocarcinoma;
  • Sihuan Pharma started a China Phase II trial of pirotinib, a novel EGFR oncology treatment, in patients with non-small cell lung cancer;
  • CANbridge Life Sciences, a Beijing in-licensing company, will begin a China Phase Ib/III clinical study of a drug for esophageal squamous cell cancer;

Stock Watch

  • Loncar launched its China BioPharma ETF, a fund that gives international investors access to a diversified portfolio of 28 China-based innovative biopharmas.

Stock Symbols: (SZE: 300149) (HK: 1558) (NYSE: BX) (SHZ: 002653) (HK: 0460) (NSDQ: CHNA)

Share this with colleagues:

     
 

Shanghai ChemPartner Closes Reverse Merger with Quantum

Written by Richard Daverman, PhD, Executive Editor, Greg B. Scott.

Shanghai ChemPartner, a CRO/CMO, has closed its reverse merger with Quantum Hi-Tech China Biological for a combination of cash and stock. ChemPartner said it will have easier access to additional capital as a listed entity. Quantum makes probiotics for packaged foods, and its operations will remain separate from ChemPartner's. The merger was first announced over a year ago, though terms of the agreement have not been disclosed. All of ChemPartner's CRO/CMO operations will become part of Quantum. More details....

Stock Symbol: (SZE: 300149)



Share this with colleagues:

     
 

Adlai Nortye of Hangzhou Opens Boston Innovation Center

Written by Richard Daverman, PhD, Executive Editor, Greg B. Scott.

Adlai Nortye, a Hangzhou biopharma that describes itself as "science-driven," opened a Boston site that will serve as the target validation and translational medicine center of the company. The center will be in charge of developing new cancer treatments, especially clinical-stage immuno-oncology candidates. Adlai Nortye expects its Boston operations will help it form more partnerships with global biopharmas. The company is developing cancer immunotherapies and treatments for metabolic disease. More details....

Share this with colleagues:

     
 

More Recent Articles

Written by Richard Daverman, PhD, Executive Editor, Greg B. Scott.


 Not a ChinaBio®Today Subscriber?

Here's what you get with a paid subscription to ChinaBio® Today:
  • Website access to all current articles and commentary
  • Full access to over 2000 archived articles on the biotech industry

Greg B. Scott
Executive Editor
ChinaBio® Today


ChinaBio and ChinaBio Today are trademarks of ChinaBio LLC


Safely Unsubscribe ArchivesPreferencesContactSubscribePrivacy